SlideShare a Scribd company logo
1 of 16
Scientific  Supervisors : Prof. Dr.B.I.Polyakov Dr.M.Y. Fedyanin Presented by: Dr.Ye Hlaing Bwar Significance of Prognostic Factors in Epithelial Ovarian Cancer M.V.LOMONOSOV MOSCOW STATE UNIVERSITY Faculty of Basic Medicine
Ovarian cancer is the fifth leading cause of death from cancer in women. Leading cause of death from gynecological cancer   in United State .
Mortality  from Ovarian Cancer ,[object Object],[object Object],[object Object],[object Object]
Prognostic factor  -  any measurement  available at the time of surgery or diagnosis  that correlates with disease-free or overall  survival  and, as a result, is able to correlate  with the natural history of the disease.  (>90%) Epithelial Ovarian Cancer
Prognostic Factors in Epithelial Ovarian Cancer Prognostic Factors -  Age -  Histology -  Grade -  Stage(FIGO)  -  ECOG performance status  -  CA125 -  Ascites -  Residual disease -  Ploidy -  Type of chemotherapy - Interval debulking
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Diagnosis
Aim of Study To indentify the statistical significance prognostic factors in epithelial ovarian cancer treated with surgery and primary systemic chemotherapy.
[object Object],[object Object],[object Object],[object Object],Objectives of study
Patients and Methods ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patients and Methods Statistical Analysis -  MedCalc software (version 9.6) -  x 2  test to compare distribution of baseline characteristics -  Fisher’s exact test where appropriate -  Kaplan-Meier method for survivals, log-rank test for comparison & Cox  proportional hazard regression models for multivariate analysis Follow-up  -  every 3 months for 1 st  two years, every 6 months for next 3 yrs &  annually thereafter
Distribution of Patients Baseline Characteristics (n=55)
5 year Overall Survival Rate (n=55)
Univariate Analysis of Prognostic Factors
Significance in  Sub-group of prognostic factor
CONCLUSION 1.  Statistical Significance of Prognostic Factors Age  (P=0.028). Histology  (P=0.035). FIGO stage  (P=0.022). Ascites  (P=0.028). ,[object Object],[object Object],[object Object],2. ,[object Object],[object Object],[object Object],[object Object],3.
Thank You!

More Related Content

What's hot

Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
CSCJournals
 
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
European School of Oncology
 
632 0713 - ferreyro bl - predictive score for estimating cancer after venou...
632   0713 - ferreyro bl - predictive score for estimating cancer after venou...632   0713 - ferreyro bl - predictive score for estimating cancer after venou...
632 0713 - ferreyro bl - predictive score for estimating cancer after venou...
Debourdeau Phil
 
Innovations in Pancreatic Cancer: A Reason to Hope
Innovations in Pancreatic Cancer: A Reason to HopeInnovations in Pancreatic Cancer: A Reason to Hope
Innovations in Pancreatic Cancer: A Reason to Hope
Christopher Kanski
 

What's hot (19)

Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
Toward Integrated Clinical and Gene Expression Profiles for Breast Cancer Pro...
 
Pelvic insufficiency fracture
Pelvic insufficiency fracturePelvic insufficiency fracture
Pelvic insufficiency fracture
 
Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...
Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...
Anaesthesia considerations and Implications during Oncologic and Non-Oncologi...
 
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
Medical Students 2011 - A. Cervantes - GASTROINTESTINAL CANCER - Pancreatic C...
 
Dr. Lucas Minig
Dr. Lucas MinigDr. Lucas Minig
Dr. Lucas Minig
 
Ovarian cancer
Ovarian cancerOvarian cancer
Ovarian cancer
 
Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...
Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...
Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Can...
 
International Journal of Hepatology & Gastroenterology
International Journal of Hepatology & GastroenterologyInternational Journal of Hepatology & Gastroenterology
International Journal of Hepatology & Gastroenterology
 
Dr naseer baloch journal club
Dr naseer baloch journal clubDr naseer baloch journal club
Dr naseer baloch journal club
 
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
State of the Art Radiotherapy in the Treatment of Colorectal Cancer: What Exa...
 
632 0713 - ferreyro bl - predictive score for estimating cancer after venou...
632   0713 - ferreyro bl - predictive score for estimating cancer after venou...632   0713 - ferreyro bl - predictive score for estimating cancer after venou...
632 0713 - ferreyro bl - predictive score for estimating cancer after venou...
 
Innovations in Pancreatic Cancer: A Reason to Hope
Innovations in Pancreatic Cancer: A Reason to HopeInnovations in Pancreatic Cancer: A Reason to Hope
Innovations in Pancreatic Cancer: A Reason to Hope
 
2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot
2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot
2014 Ovarian Cancer National Conference: Launching the Women's Cancer Moonshot
 
IJET-V3I2P22
IJET-V3I2P22IJET-V3I2P22
IJET-V3I2P22
 
Management of Early Breast Cancer
Management of Early Breast CancerManagement of Early Breast Cancer
Management of Early Breast Cancer
 
Pancreatic cancer (6 October 2014)
Pancreatic cancer (6 October 2014)Pancreatic cancer (6 October 2014)
Pancreatic cancer (6 October 2014)
 
Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...
Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...
Incidence and Management of Ovarian Cancer Cases in a Tertiary Hospital- A 10...
 
Cancer de la región anal 2019
Cancer de la región anal 2019Cancer de la región anal 2019
Cancer de la región anal 2019
 
Bevacizumab plus m folfox6 versus mfolfox6 alone as first line
Bevacizumab plus m folfox6 versus mfolfox6 alone as first lineBevacizumab plus m folfox6 versus mfolfox6 alone as first line
Bevacizumab plus m folfox6 versus mfolfox6 alone as first line
 

Similar to Yehlaingbwar

Original StudyType of Breast Cancer Diagnosis, Screening,a.docx
Original StudyType of Breast Cancer Diagnosis, Screening,a.docxOriginal StudyType of Breast Cancer Diagnosis, Screening,a.docx
Original StudyType of Breast Cancer Diagnosis, Screening,a.docx
vannagoforth
 
ca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.ppt
MusaibMushtaq
 
A retrospective study on ovarian cancer with a median follow-up of 36 months ...
A retrospective study on ovarian cancer with a median follow-up of 36 months ...A retrospective study on ovarian cancer with a median follow-up of 36 months ...
A retrospective study on ovarian cancer with a median follow-up of 36 months ...
AI Publications
 

Similar to Yehlaingbwar (20)

Original StudyType of Breast Cancer Diagnosis, Screening,a.docx
Original StudyType of Breast Cancer Diagnosis, Screening,a.docxOriginal StudyType of Breast Cancer Diagnosis, Screening,a.docx
Original StudyType of Breast Cancer Diagnosis, Screening,a.docx
 
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...
 
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCERROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
ROLE OF NEOADJUVANT CHEMORADIATION IN LOCALLY ADVANCED BREAST CANCER
 
Breast N C C Nguidlinesms1
Breast N C C Nguidlinesms1Breast N C C Nguidlinesms1
Breast N C C Nguidlinesms1
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
 
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
Benefit of Serum-Thymidine Kinase 1 Concentration for Risk Assessment from Ga...
 
ca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.ppt
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Prostate cancer 2018: A brief overview
Prostate cancer 2018: A brief overviewProstate cancer 2018: A brief overview
Prostate cancer 2018: A brief overview
 
Evolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screeningEvolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screening
 
The Continuous Update Project | Prof. Martin Wiseman
The Continuous Update Project | Prof. Martin WisemanThe Continuous Update Project | Prof. Martin Wiseman
The Continuous Update Project | Prof. Martin Wiseman
 
A retrospective study on ovarian cancer with a median follow-up of 36 months ...
A retrospective study on ovarian cancer with a median follow-up of 36 months ...A retrospective study on ovarian cancer with a median follow-up of 36 months ...
A retrospective study on ovarian cancer with a median follow-up of 36 months ...
 

Recently uploaded

Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
AnaAcapella
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
ZurliaSoop
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
negromaestrong
 

Recently uploaded (20)

Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
 
Spatium Project Simulation student brief
Spatium Project Simulation student briefSpatium Project Simulation student brief
Spatium Project Simulation student brief
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Dyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxDyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptx
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 

Yehlaingbwar

  • 1. Scientific Supervisors : Prof. Dr.B.I.Polyakov Dr.M.Y. Fedyanin Presented by: Dr.Ye Hlaing Bwar Significance of Prognostic Factors in Epithelial Ovarian Cancer M.V.LOMONOSOV MOSCOW STATE UNIVERSITY Faculty of Basic Medicine
  • 2. Ovarian cancer is the fifth leading cause of death from cancer in women. Leading cause of death from gynecological cancer in United State .
  • 3.
  • 4. Prognostic factor - any measurement available at the time of surgery or diagnosis that correlates with disease-free or overall survival and, as a result, is able to correlate with the natural history of the disease. (>90%) Epithelial Ovarian Cancer
  • 5. Prognostic Factors in Epithelial Ovarian Cancer Prognostic Factors - Age - Histology - Grade - Stage(FIGO) - ECOG performance status - CA125 - Ascites - Residual disease - Ploidy - Type of chemotherapy - Interval debulking
  • 6.
  • 7. Aim of Study To indentify the statistical significance prognostic factors in epithelial ovarian cancer treated with surgery and primary systemic chemotherapy.
  • 8.
  • 9.
  • 10. Patients and Methods Statistical Analysis - MedCalc software (version 9.6) - x 2 test to compare distribution of baseline characteristics - Fisher’s exact test where appropriate - Kaplan-Meier method for survivals, log-rank test for comparison & Cox proportional hazard regression models for multivariate analysis Follow-up - every 3 months for 1 st two years, every 6 months for next 3 yrs & annually thereafter
  • 11. Distribution of Patients Baseline Characteristics (n=55)
  • 12. 5 year Overall Survival Rate (n=55)
  • 13. Univariate Analysis of Prognostic Factors
  • 14. Significance in Sub-group of prognostic factor
  • 15.